Harrow Inc (HROW) Stock Price, Quote & News

Company Profile

Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products. The company offers ImprimisRx, an ophthalmology-focused compounded medications. It provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, including IOPIDINE, VEVYE, and ZERVIATE; MAXITROL eye drops; ILEVRO and NEVANAC, a non-steroidal and anti-inflammatory eye drop for pain and inflammation associated with cataract sur...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 615 733 4730

Website: www.harrow.com

Address:

1A Burton Hills Boulevard, Suite 200, Nashville, United States

sprk517 Oct. 25 at 11:11 AM

$HROW Take a shot whenever @Finnish_boy says "SP $100 next year". 😆 (just some friendly banter)

1 · Reply

Finnish_boy Oct. 25 at 10:15 AM

$HROW Current SP has priced in VEVYE. Other drugs are bonus assets. IHEEZO, TRIESENCE, MELT-300, BIOSIMILARS, BYQLOVI, ImprimisRX whatever are free lunch. Lets see when there is fair market pricing. Some longs sell the stock because they know they can buy back lower due to manipulation and under radar status. Stock markets are not fair game. But time will heal this stock. We are close now. Q3 report can be the trigger. Next year $100 for sure.

0 · Reply

Finnish_boy Oct. 25 at 7:47 AM

$HROW This is my conservative road map. My best guess is that Q3 will be around 73-74M and stock heading to $50. Baum and Boll will be extremely bullish about outlook. Institutions will load up after Q3 report. New ATH this year, $70 is possible for sure. Next year $100. Easy money. Buying every potential dip. Market pricing doesnt work yet. SP need to double now. It wont though because under radar name.

1 · Reply

Fullback Oct. 25 at 6:41 AM

$HROW Doing some noodling on H1 vs H2 sales and growth required to meet $280M guidance. Vevye must grow at least 50% from H1 to H2. IHEEZO must grow at least 14% from H1 to H2. Specialty Branded + 3E must grow at least 809% from H1 to H2. Imprimis RX can't shrink more than 8% from H1 to H2. That SB + 3e seems like a tall hill to climb % wise, but its coming off a small base...I'm hoping they achieve this...seems like this growth is all on 3e.

2 · Reply

Finnish_boy Oct. 24 at 9:43 PM

$HROW I use these estimates. I think SP hits new ATH this year and next year $100. Harrow has gained more and more analyst coverage and talented invidual investors so i am very confident price action going ahead. Markets pricing has to kick in. But if there was any bigger dip after Q3 report, i would go again all in. But i think SP heading to $50.

1 · Reply

Finnish_boy Oct. 24 at 8:21 PM

$HROW Short-sellers maybe try to play weak Q3 report. I think revenue will be 73-74M but revenue can be anything between 68-78m. If revenue would be 68-70m, you have to sell wife's jewellery for buying potential dip. But imo we dont have any dip because current SP doesnt price in anything. I think SP hits new ATH this year.

1 · Reply

Fullback Oct. 24 at 8:14 PM

$HROW Almost 21% of the float short.

1 · Reply

Fullback Oct. 24 at 8:12 PM

$HROW Bought again at $38.42, ~$1500 worth.

0 · Reply

Finnish_boy Oct. 24 at 7:10 PM

$HROW You can check short interest 16 pm ET https://www.nasdaqtrader.com/Trader.aspx?id=ShortInterest

1 · Reply

Finnish_boy Oct. 24 at 5:49 PM

$HROW Interesting short report after close.. lets see

1 · Reply

Harrow: Positive And Negative Adjustments After Investor Day Offset Each Other

Oct 6, 2025, 7:00 AM EDT - 19 days ago

ImprimisRx Announces Leadership Changes

Sep 27, 2025, 12:27 AM EDT - 4 weeks ago

Harrow, Inc. (HROW) Analyst/Investor Day Transcript

Sep 26, 2025, 7:00 AM EDT - 4 weeks ago

Harrow to Acquire Melt Pharmaceuticals

Sep 25, 2025, 4:05 PM EDT - 4 weeks ago

Harrow Launches Harrow Access for All (HAFA)

Sep 15, 2025, 7:00 AM EDT - 5 weeks ago

Harrow Announces Agenda and Speakers for Investor & Analyst Day

Sep 12, 2025, 10:57 AM EDT - 6 weeks ago

Harrow: Buy A Blend Of Value And Growth

Sep 9, 2025, 1:11 PM EDT - 6 weeks ago

Harrow: A Classical GARP Stock

Sep 8, 2025, 5:57 PM EDT - 6 weeks ago

Harrow Announces Pricing of $250.0 Million Offering of Senior Unsecured Notes Due 2030

Sep 8, 2025, 8:00 AM EDT - 6 weeks ago

Harrow Announces Offering of $250.0 Million Senior Unsecured Notes Due 2030

Aug 14, 2025, 11:09 PM EDT - 2 months ago

Harrow's Ambitious Guidance Puts It In The Proving Ground

Aug 13, 2025, 5:39 PM EDT - 2 months ago

Harrow: Exciting Times In Store

Aug 12, 2025, 2:47 PM EDT - 2 months ago

Harrow, Inc. (HROW) Q2 2025 Earnings Call Transcript

Aug 11, 2025, 4:01 PM EDT - 2 months ago

Harrow Announces Second-Quarter 2025 Financial Results

Aug 6, 2025, 7:00 AM EDT - 2 months ago

Harrow to Present at H.C. Wainwright 5th Annual Ophthalmology Conference

Jul 29, 2025, 7:00 AM EDT - 3 months ago

Harrow To Report Second Quarter 2025 Financial Results After Market Close on August 11, 2025

Jul 17, 2025, 7:00 AM EDT - 3 months ago

Harrow Enters into Commercialization Agreement with Samsung Bioepis for Ophthalmology Biosimilars Portfolio in the United States

Jul 17, 2025, 7:00 AM EDT - 3 months ago

Samsung Bioepis Enters into a Partnership with Harrow for Commercialization of Ophthalmology Biosimilars Portfolio in the United States

Jul 15, 2025, 10:38 AM EDT - 3 months ago

HROW Investors Have Opportunity to Join Harrow, Inc. Fraud Investigation with the Schall Law Firm

Jul 11, 2025, 5:47 PM EDT - 3 months ago

Harrow's Internal $100 Price Target Is Ambitious, But New Bloomberg Data Backs It Up

Jul 9, 2025, 2:52 PM EDT - 3 months ago

Harrow: Immense Upside Potential

Jun 18, 2025, 7:00 AM EDT - 4 months ago

Harrow Appoints Mike Biega as Vice President of Investor Relations and Communications

Jun 13, 2025, 8:30 AM EDT - 4 months ago

I Am Swimming In Dividends With +7% Yields

UMH

Jun 9, 2025, 7:00 AM EDT - 4 months ago

Harrow Acquires U.S. Commercial Rights to BYQLOVI™ (Clobetasol Propionate Ophthalmic Suspension) 0.05% from Formosa Pharmaceuticals

May 28, 2025, 3:20 PM EDT - 5 months ago

Harrow: Epic Growth & Operating Leverage On Full Display

May 14, 2025, 7:00 AM EDT - 5 months ago

Harrow to Present at Two Investor Conferences in May

May 10, 2025, 6:17 PM EDT - 5 months ago

Harrow, Inc. (HROW) Q1 2025 Earnings Call Transcript

May 8, 2025, 4:01 PM EDT - 6 months ago

Harrow Announces First-Quarter 2025 Financial Results

May 5, 2025, 7:00 AM EDT - 6 months ago

Harrow to Report First Quarter 2025 Financial Results After Market Close on May 8, 2025

Apr 24, 2025, 10:00 AM EDT - 6 months ago

NORDIC GROUP B.V. THROUGH ITS SUBSIDIARY NORDIC PHARMA, INC.

Apr 10, 2025, 7:00 AM EDT - 7 months ago

Harrow Expands VEVYE® Access for All Program to ImprimisRx's Klarity-C Patients

Mar 29, 2025, 4:30 PM EDT - 7 months ago

Harrow: When Cheaper Doesn't Mean Attractive (Rating Upgrade)

Mar 28, 2025, 2:00 PM EDT - 7 months ago

Harrow, Inc. (HROW) Q4 2024 Earnings Conference Call

Mar 28, 2025, 1:39 PM EDT - 7 months ago

Harrow Inc.: Roll The Dice For Strong Upside Prospects As Earnings Ramp

Mar 27, 2025, 4:01 PM EDT - 7 months ago

Harrow Announces Fourth-Quarter and Year-End 2024 Audited Financial Results

Mar 27, 2025, 10:45 AM EDT - 7 months ago

Harrow To Report Fourth Quarter and Audited Year-End 2024 Financial Results After Market Close on March 27, 2025

Mar 24, 2025, 7:00 AM EDT - 7 months ago

Harrow Announces Transitional Pass-Through Reimbursement Status for TRIESENCE® (Triamcinolone Acetonide Injectable Suspension) 40 mg/mL

Mar 17, 2025, 4:01 PM EDT - 7 months ago

Harrow Provides Fourth Quarter and Year-End 2024 Unaudited Preliminary Financial Results and 2025 Revenue Guidance

Mar 17, 2025, 7:00 AM EDT - 7 months ago

Harrow Launches VEVYE® Access for All

Mar 11, 2025, 7:00 AM EDT - 8 months ago

Harrow Executes Five-Year Strategic Supply and Development Agreement for TRIESENCE®

Mar 3, 2025, 7:15 AM EST - 8 months ago

Harrow to Report Fourth Quarter and Year-End 2024 Financial Results After Market Close on March 17, 2025

Mar 1, 2025, 8:50 AM EST - 8 months ago

Smallcap Eyecare Pharma Company Harrow Health Has Two Major Catalysts For 2025

Jan 27, 2025, 7:30 AM EST - 9 months ago

Harrow Partners with Cencora to Launch “Harrow Cares” Program, Making IHEEZO® and TRIESENCE® More Accessible and Affordable for Retina Specialists and Their Patients

COR

Jan 7, 2025, 7:00 AM EST - 10 months ago

Harrow Appoints Amir H. Shojaei as Chief Scientific Officer

Jan 3, 2025, 3:43 PM EST - 10 months ago

Those Derisked Baby Bonds Of Harrow, Inc.

Dec 14, 2024, 12:09 AM EST - 11 months ago

Harrow: The Triesence Relaunch

Nov 21, 2024, 7:00 AM EST - 1 year ago

Harrow's ImprimisRx Subsidiary Receives $34.9 Million Unanimous Jury Verdict Award in ImprimisRx, LLC v. OSRX, Inc.

sprk517 Oct. 25 at 11:11 AM

$HROW Take a shot whenever @Finnish_boy says "SP $100 next year". 😆 (just some friendly banter)

1 · Reply

Finnish_boy Oct. 25 at 10:15 AM

0 · Reply

Finnish_boy Oct. 25 at 7:47 AM

1 · Reply

Fullback Oct. 25 at 6:41 AM

2 · Reply

Finnish_boy Oct. 24 at 9:43 PM

1 · Reply

Finnish_boy Oct. 24 at 8:21 PM

1 · Reply

Fullback Oct. 24 at 8:14 PM

$HROW Almost 21% of the float short.

1 · Reply

Fullback Oct. 24 at 8:12 PM

$HROW Bought again at $38.42, ~$1500 worth.

0 · Reply

Finnish_boy Oct. 24 at 7:10 PM

$HROW You can check short interest 16 pm ET https://www.nasdaqtrader.com/Trader.aspx?id=ShortInterest

1 · Reply

Finnish_boy Oct. 24 at 5:49 PM

$HROW Interesting short report after close.. lets see

1 · Reply

mutallim Oct. 24 at 5:44 PM

$PGY $DLO $HROW time to start

0 · Reply

sprk517 Oct. 24 at 2:09 PM

$HROW Anyone eyeing or owning some calls? April '26 and Jan '27 could be interesting. Q4 '25 results and '26 outlook could be a decent catalyst.

1 · Reply

Alberthansson02 Oct. 24 at 2:05 PM

$HROW where is the volume?!

2 · Reply

Clarkkent89 Oct. 24 at 1:37 PM

$HROW Selling names that are pumping to buy more of HROW here

0 · Reply

Fullback Oct. 23 at 10:31 PM

$HROW A little over 1/3 the avg volume today.....light!

0 · Reply

Fullback Oct. 22 at 7:23 PM

$HROW Added ~ 40 shares at $38.60.

1 · Reply

Finnish_boy Oct. 22 at 10:55 AM

$HROW I want to remind that ImprismisRX is best in class in eye compounded business. Recalls are totally normal for compounded business. The California case is mostly FUD and just coincidence considering the timing of CEO change. Quality team the behind of quality, not CEO. Harrow has recruited two talented quality experts this year. CEO change had been prepared for long time imho. ImprimisRX is doing awesome.

2 · Reply

Fullback Oct. 21 at 10:06 PM

$HROW The more I think about the ImprimisRx fiasco, JS was a sales guy, not an operational guy. Not the right guy for the right job. Thus the repetitive violations and mis steps. Surprised MB couldn't recognize this due to his proximity to JS. New folks will clean this up I bet I'll be expecting better compliance results.

3 · Reply

Tennis_4567 Oct. 21 at 4:59 PM

$HROW super low volume here on a little pullback which is nice to see. Unless there’s a catalyst in the next few weeks I’d expect this to trade sideways until earnings. Next short report out Friday

0 · Reply

Fullback Oct. 20 at 11:13 PM

$HROW About 4/5 Avg 90 day volume today along with a nice SP increase. Interesting to see how this trades as Q3 CC approaches.

1 · Reply

tupelo3 Oct. 20 at 5:57 PM

$HROW Can someone tell me what analyst estimates for iheezo peak sales are?

6 · Reply

Fullback Oct. 18 at 3:21 AM

$HROW Trading volume has really picked up on $HROW Google Finance's 30 day average: Yahoo's 90 day average:

1 · Reply

Market Cap	1.44B
Revenue (ttm)	199.61M
Net Income (ttm)	-17.48M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	91.15
Profit Margin	-8.76%
Debt to Equity Ratio	0.78

Volume	527,500
Avg Vol	706,812
Day's Range	N/A - N/A
Shares Out	37.00M
Stochastic %K	28%
Beta	0.27
Analysts	Strong Sell
Price Target	$67.91